ArticleJournal of clinical pharmacology2020
Clinical Pharmacology and Safety of Trifarotene, a First-in-Class RARγ-Selective Topical Retinoid.
Article in Journal of clinical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Bridging Gaps in Malaysian Acne Vulgaris Guidelines: Advisory Statements on Trifarotene for Facial and Truncal Acne.Journal of cosmetic dermatology · 2026Guideline
- Review
- Retinoids in scarless skin regeneration: from molecular mechanisms to therapeutic strategies.Frontiers in cell and developmental biology · 2025Review
- Review
- Attempts to Improve Lipophilic Drugs' Solubility and Bioavailability: A Focus on Fenretinide.Pharmaceutics · 2024Review
- Consensus Report on Truncal Acne: The Korean Acne and Rosacea Society Experts Panel.Annals of dermatology · 2024Article
- Acne treatment: research progress and new perspectives.Frontiers in medicine · 2024Review
- Palovarotene Action Against Heterotopic Ossification Includes a Reduction of Local Participating Activin A-Expressing Cell Populations.JBMR plus · 2023Article
- Synthetic Retinoids Beyond Cancer Therapy.Annual review of pharmacology and toxicology · 2022Review
- Trifarotene: A Novel Therapeutic Option for Acne.Dermatology research and practice · 2022Review
- Trifarotene: A Current Review and Perspectives in Dermatology.Biomedicines · 2021Review
- Assessing the Safety and Efficacy of Trifarotene in the Treatment of Acne Vulgaris.Therapeutics and clinical risk management · 2021Review
- Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine.Nature communications · 2020Review
- Management of Acne Vulgaris With Trifarotene.Journal of cutaneous medicine and surgeryReview
- A Clinician's Guide to Topical Retinoids.Journal of cutaneous medicine and surgeryReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Trifarotene is a new drug with retinoic acid receptor activity and selectivity for retinoic acid receptor-γ. The reported studies aimed at assessing the clinical pharmacology and safety of trifarotene. The clinical pharmacology of topical trifarotene up to 100 µg/g was extensively investigated through 2 maximal usage pharmacokinetic trials (MUsT) conducted in adult (≥18 years) and pediatric patients (9-17 years) with moderate to severe acne and two studies conducted in healthy volunteers: 1 thorough QT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.